<code id='49BD3EA940'></code><style id='49BD3EA940'></style>
    • <acronym id='49BD3EA940'></acronym>
      <center id='49BD3EA940'><center id='49BD3EA940'><tfoot id='49BD3EA940'></tfoot></center><abbr id='49BD3EA940'><dir id='49BD3EA940'><tfoot id='49BD3EA940'></tfoot><noframes id='49BD3EA940'>

    • <optgroup id='49BD3EA940'><strike id='49BD3EA940'><sup id='49BD3EA940'></sup></strike><code id='49BD3EA940'></code></optgroup>
        1. <b id='49BD3EA940'><label id='49BD3EA940'><select id='49BD3EA940'><dt id='49BD3EA940'><span id='49BD3EA940'></span></dt></select></label></b><u id='49BD3EA940'></u>
          <i id='49BD3EA940'><strike id='49BD3EA940'><tt id='49BD3EA940'><pre id='49BD3EA940'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:18

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In